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Thirty women with ductal carcinoma-in-situ (DCIS) diag-
nosed by minimally invasive biopsy techniques are being
recruited for an IRB approved study testing the effects of
neoadjuvant pegylated liposomal doxorubicin (Doxil)
delivered through the affected duct on histology and
imaging. Pre-procedure MRI and mammography are
obtained on consenting women with a core biopsy dem-
onstrating DCIS. The affected duct is cannulated and a
ductogram performed to document both absence of per-
foration and presence of dye in the diseased duct. 20 mg
(10 cc) of Doxil is then instilled into the duct. Patients are
observed for one hour, and examined in about 24 hours.
They have continuous access to study staff to report symp-
toms, and periodic contact is made with them to verify
their status. Four to six weeks later, just prior to surgery,
the mammogram, MRI and CBC are repeated. At opera-
tion, ductoscopy is performed and the duct identified for
the pathologist. India ink gel is instilled immediately after
the tissue is removed in order to identify the treated duct
on histology. Three of the thirty patients will be rand-
omized to receive normal saline instead of Doxil in a
blinded fashion.
To date, six women have consented to the study. The first
was not treated because of technical difficulties with the
ductogram. Of the remaining five women two sustained
perforated ducts and were not treated; two received the
full dose of drug into the correct duct and one had a
smaller dose into an adjacent duct. The treatment has
been very well-tolerated. One fully treated patient had an
inflammatory reaction in the treated area three weeks after
Doxil administration. The episode lasted about 24 hours
and responded to anti-inflammatory medication. Subse-
quent histology at the time of lumpectomy surgery 6
weeks later verified the presence of inflammation, squa-
mous metaplasia and fat necrosis.
This study, sponsored by the Dr. Susan Love Research
Foundation (DSLRF) and funded by the California Breast
Cancer Research Program (CBCRP), is taking place in an
isolated, economically-challenged and medically-unders-
erved area. The presence of high-level original research in
the local area has been a source of pride to the community
as a whole, and the work validates the ideals of the CBCRP
and the DSLRF. Support from local clinicians has been
substantial, and the work maintains high visibility.
In summary, this research is feasible in a community set-
ting. We are testing the concept of using the ductal system
itself as a drug delivery system to affect the natural history
of a disease confined to the duct. We are testing our ability
to correctly identify the orifice of the affected duct by
inspection of the mammogram. The treatment appears to
be well-tolerated by the patients, and does not appear to
affect the mammographic appearance of the breast
despite documented cell death.
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